Update on hepatitis C virus management

被引:0
作者
Peer, Austin D. [1 ]
Price, Jennifer C. [1 ]
机构
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
关键词
direct-acting antivirals; hepatitis C virus; hepatitis C virus elimination; simplified hepatitis C virus treatment algorithm; REINFECTION; INFECTION;
D O I
10.1097/MOG.0000000000001098
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Purpose of reviewDespite the efficacy of direct-acting antiviral (DAA) therapy, hepatitis C virus (HCV) remains a significant contributor to liver-related morbidity and mortality. This review summarizes the approach to HCV treatment, the simplified treatment algorithm for most patients, the management of special populations, and future directions for HCV interventions.Recent findingsPan genotypic DAA regimens have high cure rates and can be managed by nonspecialist providers, and the simplified treatment approach provides a clear algorithm for workup and treatment decisions among treatment-naive patients without decompensated cirrhosis. Additionally, advancements in point of care diagnostics have the potential to further expand access to screening and linkage to care. Despite these breakthroughs, barriers to accessing care and the stigmatization of high-risk populations continue to undercut progress towards HCV elimination. Continued implementation of innovative screening and treatment strategies are required to overcome rising HCV prevalence.SummaryHCV cure is achievable for nearly all patients, but reaching HCV elimination goals will require a comprehensive approach that increases screening, expands access to simplified treatment, and avoids stigmatization of at-risk populations. Targeting healthcare disparities and removing barriers to treatment uptake are crucial to achieving elimination targets.
引用
收藏
页码:265 / 270
页数:6
相关论文
共 22 条
[1]  
[Anonymous], Recommendations for testing, managing, and treating hepatitis C
[2]   Expanding Access to Hepatitis C Virus Treatment-Extension for Community Healthcare Outcomes (ECHO) Project: Disruptive Innovation in Specialty Care [J].
Arora, Sanjeev ;
Kalishman, Summers ;
Thornton, Karla ;
Dion, Denise ;
Murata, Glen ;
Deming, Paulina ;
Parish, Brooke ;
Brown, John ;
Komaromy, Miriam ;
Colleran, Kathleen ;
Bankhurst, Arthur ;
Katzman, Joanna ;
Harkins, Michelle ;
Curet, Luis ;
Cosgrove, Ellen ;
Pak, Wesley .
HEPATOLOGY, 2010, 52 (03) :1124-1133
[3]   Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases- Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection [J].
Bhattacharya, Debika ;
Aronsohn, Andrew ;
Price, Jennifer ;
Lo Re, Vincent, III .
CLINICAL INFECTIOUS DISEASES, 2023,
[4]   Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study [J].
Blach, Sarah ;
Terrault, Norah A. ;
Tacke, Frank ;
Gamkrelidze, Ivane ;
Craxi, Antonio ;
Tanaka, Junko ;
Waked, Imam ;
Dore, Gregory J. ;
Abbas, Zaigham ;
Abdallah, Ayat R. ;
Abdulla, Maheeba ;
Aghemo, Alessio ;
Aho, Inka ;
Akarca, Ulus S. ;
Alalwan, Abduljaleel M. ;
Blome, Marianne Alanko ;
Al-Busafi, Said A. ;
Aleman, Soo ;
Alghamdi, Abdullah S. ;
Al-Hamoudi, Waleed K. ;
Aljumah, Abdulrahman A. ;
Al-Naamani, Khalid ;
Al Serkal, Yousif M. ;
Altraif, Ibrahim H. ;
Anand, Anil C. ;
Anderson, Motswedi ;
Andersson, Monique, I ;
Athanasakis, Kostas ;
Baatarkhuu, Oidov ;
Bakieva, Shokhista R. ;
Ben-Ari, Ziv ;
Bessone, Fernando ;
Biondi, Mia J. ;
Bizri, Abdul Rahman N. ;
Mello, Carlos E. Brandaoo ;
Brigida, Krestina ;
Brown, Kimberly A. ;
Brown, Robert S., Jr. ;
Bruggmann, Philip ;
Brunetto, Maurizia R. ;
Busschots, Dana ;
Buti, Maria ;
Butsashvili, Maia ;
Cabezas, Joaquin ;
Chae, Chungman ;
Ivanova, Viktorija Chaloska ;
Chan, Henry Lik Yuen ;
Cheinquer, Hugo ;
Cheng, Kent Jason ;
Cheon, Myeong Eun .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (05) :396-415
[5]   A National Hepatitis C Elimination Program in the United States A Historic Opportunity [J].
Fleurence, Rachael L. ;
Collins, Francis S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (15) :1251-1252
[6]   Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials [J].
Gane, Edward ;
de Ledinghen, Victor ;
Dylla, Douglas E. ;
Rizzardini, Giuliano ;
Shiffman, Mitchell L. ;
Barclay, Stephen T. ;
Calleja, Jose Luis ;
Xue, Zhenyi ;
Burroughs, Margaret ;
Gutierrez, Julio A. .
JOURNAL OF VIRAL HEPATITIS, 2021, 28 (11) :1635-1642
[7]   Estimating hepatitis C prevalence in the United States, 2017-2020 [J].
Hall, Eric W. ;
Bradley, Heather ;
Barker, Laurie K. ;
Lewis, Karon C. ;
Shealey, Jalissa ;
Valverde, Eduardo ;
Sullivan, Patrick ;
Gupta, Neil ;
Hofmeister, Megan G. .
HEPATOLOGY, 2024, :625-636
[8]  
hhs, HHS National Viral Hepatitis Action Plan, 2017-2020
[9]   HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe [J].
Ingiliz, Patrick ;
Martin, Thomas C. ;
Rodger, Alison ;
Stellbrink, Hans-Juergen ;
Mauss, Stefan ;
Boesecke, Christoph ;
Mandorfer, Mattias ;
Bottero, Julie ;
Baumgarten, Axel ;
Bhagani, Sanjay ;
Lacombe, Karine ;
Nelson, Mark ;
Rockstroh, Juergen K. .
JOURNAL OF HEPATOLOGY, 2017, 66 (02) :282-287
[10]  
iris.who, 2016, Global health sector strategy on viral hepatitis 2016-2021